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S U M M A R Y
Objective: To estimate the prevalence of Pseudomonas aeruginosa and antimicrobial-resistant P.
aeruginosa in ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), and
community-acquired pneumonia (CAP) in mainland China.
Methods: Meta-analyses of 50 studies published from 2010 to 2014 were conducted, followed by pre-
deﬁned subgroup analyses and meta-regressions.
Results: P. aeruginosa accounted for 19.4% (95% conﬁdence interval (CI) 17.6–21.2%) of all isolates in VAP,
which was similar to the proportion in HAP of 17.8% (95% CI 14.6–21.6%), but signiﬁcantly greater than
the proportion in CAP of 7.7% (15/195, p < 0.001). Regarding VAP, the prevalence of P. aeruginosa has
decreased since 2007. P. aeruginosa exhibited varying resistance to agents recommended for the initial
management of VAP, with a high level of resistance to gentamicin (51.1%, 95% CI 37.7–64.4%) and a low
level of resistance to amikacin (22.5%, 95% CI 14.3–33.6%). The prevalence of P. aeruginosa isolates
resistant to agents recommended for the treatment of HAP ranged from 22.2% (95% CI 13.8–33.6%) for
amikacin to 50.0% (95% CI 30.2–69.8%) for cefoperazone.
Conclusions: P. aeruginosa was highly prevalent among patients with VAP and HAP in mainland China.
The initial empirical treatment of these patients remains challenging because of the strikingly high
prevalence of antimicrobial resistance.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pneumonia is an acute inﬂammation of the lungs caused by a
wide spectrum of pathogens, which can be divided into two main
types: hospital-acquired pneumonia (HAP) and community-
acquired pneumonia (CAP). HAP is a respiratory infection that
develops more than 48 h after hospital admission, occurs at a rate of
5–10 cases per 1000 hospitalizations, and is the second most
common nosocomial infection in the USA.1 HAP is also associated
with mechanical ventilation, in which case it is termed ventilator-
associated pneumonia (VAP). The global incidence of VAP ranges* Corresponding author. Tel./fax.: +86 10 82805162.
E-mail address: siyan-zhan@bjmu.edu.cn (S. Zhan).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).from 8% to 28%,2 while the mortality varies from 24% to 76%.3 CAP
arises in those infected by pathogens who have not been recently
hospitalized. In studies from Europe and North America, the annual
incidence of CAP is 34–40 cases per 1000 children,4 and the
condition accounts for about 500 000 hospital admissions annually.5
Pseudomonas aeruginosa is one of the most frequent Gram-
negative pathogens responsible for nosocomial pneumonia.6
According to data reported by the National Healthcare Safety
Network (NHSN), P. aeruginosa (16.6%) ranked second in the USA
among the pathogens isolated from VAP patients from 2009 to
2010.7 In comparison, the prevalence of P. aeruginosa in CAP is
much lower. P. aeruginosa was the pathogen in only 0.05% of
patients with CAP.8
Initial empirical antimicrobial therapy is commonly recom-
mended in guidelines for the management of pneumonia.1,9–12ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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should include a selected b-lactam plus either an antipseudo-
monal quinolone or an aminoglycoside.10–12 However, P. aeru-
ginosa pneumonia is becoming difﬁcult to treat because of the
increasing prevalence of drug resistance and the resultant limited
therapeutic options.13 Terms such as ‘multidrug resistance’
(MDR), ‘extensive drug resistance’ (XDR), and ‘pan-drug resis-
tance’ (PDR) are used to characterize the different patterns of
multiple drug resistance exhibited by P. aeruginosa. According to
the deﬁnitions proposed by the European Centre for Disease
Prevention and Control (ECDC), MDR refers to an organism’s non-
susceptibility to at least one agent in three or more antimicrobial
categories, XDR indicates non-susceptibility to at least one agent
in all but two or fewer antimicrobial categories, and PDR suggests
non-susceptibility  to all agents in all antimicrobial categories.14
In Asia, the MDR, XDR, and PDR rates of P. aeruginosa involved in
nosocomial pneumonia are reportedly 42.8%, 4.9%, and 0.7%,
respectively.15 In addition, resistant and MDR P. aeruginosa
infections have been ﬁrmly associated with an increased
mortality and a longer length of hospital stay.13 To achieve
optimal empirical antimicrobial therapy, it is therefore important
to understand the pathogen distribution and drug susceptibility
patterns of pneumonia.9
In mainland China, data from the National Nosocomial Infection
Surveillance System (NNISS) indicated that P. aeruginosa ranked
top among pathogens identiﬁed from the lower respiratory tract, at
12.82% from 1999 to 2001, 12.31% during the period from 2002 to
2004, and 13.37% from 2005 to 2007.16 In addition, of the 7270 P.
aeruginosa isolates collected from 15 teaching hospitals in 2012,
13.5–34.5% were resistant to at least one of the agents tested and
80 isolates showed PDR.17 Despite descriptions of the epidemio-
logical characteristics of P. aeruginosa in previous studies,
substantial uncertainty remains in the epidemiology of P.
aeruginosa pneumonia. It appears that there is only one systematic
review dealing with the prevalence of P. aeruginosa in VAP, with an
estimate of 20.6% for the period 2007–2012;18 none has been
conducted to investigate the antimicrobial resistance patterns in
relation to P. aeruginosa pneumonia. In this regard, the present
systematic review aimed to provide further details in this ﬁeld and
to promote appropriate empirical antimicrobial therapy by
estimating the prevalence of P. aeruginosa and antimicrobial-
resistant P. aeruginosa in different types of pneumonia in mainland
China.
2. Methods
2.1. Literature search and eligibility criteria
The following ﬁve electronic databases were searched system-
atically for relevant studies: MEDLINE, EMBASE, Chinese BioMedi-
cal Database (CBM), China National Knowledge Infrastructure
(CNKI), and Wanfang Database. Given the focus on the recent
epidemiological characteristics of P. aeruginosa pneumonia in this
review, searches were limited to studies published between
January 2010 and December 2014. The searches were based on the
following terms related to this review: ‘Pseudomonas aeruginosa’,
‘Pneumonia OR Pneumon*(truncated term)’ and ‘China OR Chinese
OR Han Chinese’. Combinations of medical subject heading (MeSH)
and free-text terms were applied to MEDLINE, EMBASE, and CBM,
and free-text terms were used to search CNKI and Wanfang
Database. The full search strategies for each database are listed in
the Supplementary Material (Table S1).
Reviewers were divided into two groups that worked in
parallel. The reviewers independently screened each record by
title, keywords, and abstract against the eligibility criteria. Full
texts were referred to when information in the records wasinadequate for determination. Any disagreement between the two
groups of reviewers was resolved by an additional reviewer. A ﬂow
chart for study inclusion was developed in line with the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) statement.19
Studies were included if they met all of the following criteria:
(1) Study patients with any type of pneumonia (VAP, HAP, or
CAP) infected by P. aeruginosa. (2) Study reporting available and
sufﬁcient data to calculate the prevalence of P. aeruginosa, the
prevalence of MDR/XDR/PDR P. aeruginosa, or the prevalence of P.
aeruginosa isolates resistant to a given agent in a speciﬁc type of
pneumonia. Based on the clinical practice guidelines prepared by
the Chinese Medical Association,10–12 the agents were limited to
those recommended for the initial management of suspected P.
aeruginosa pneumonia in a Chinese population, which included
b-lactams (cefoperazone, cefepime, ceftazidime, piperacillin,
imipenem, meropenem, cefoperazone–sulbactam, and pipera-
cillin–tazobactam), antipseudomonal quinolones (levoﬂoxacin
and ciproﬂoxacin), and aminoglycosides (amikacin and genta-
micin). (3) Data collected in a prospective manner with a study
design of surveillance, ambispective or prospective cohort study,
nested case–control study, cross-sectional study, or baseline of
randomized controlled trial (RCT). (4) Studies conducted in
mainland China. (5) Investigations published in Chinese or
English.
2.2. Data extraction
An extraction form was pre-designed using EpiData 3.1 (The
EpiData Association, Odense, Denmark) and then modiﬁed
following a pilot test. The revised extraction form comprised four
parts: general information, methodological quality, clinical char-
acteristics, and data for calculating the prevalence of P. aeruginosa
and corresponding antimicrobial-resistant isolates. The data
extraction procedure was also implemented independently by
the two parallel groups of reviewers. Any disagreement was
resolved by an additional reviewer.
2.3. Risk of bias assessment
The methodological quality of each included study was
assessed using the modiﬁed Leboeuf-Yde and Lauritsen tool,20
which consists of 10 items addressing two study dimensions
(external validity and internal validity) plus a summary risk of bias
assessment (Supplementary Material, File S1).21 Each item can be
judged as having a low or a high risk of bias. One point was
awarded if an item was judged to have a low risk of bias, and the
maximum score was 10 points. Studies with a score of 8, 6–7, and
5 points were considered to have a low, moderate, and high risk
of bias, respectively.22 Graphs of the summary of the risk of bias
were developed using RevMan 5.3 (Cochrane Informatics and
Knowledge Management Department, London, UK).
2.4. Statistical analysis
All analyses were performed with R 3.2.1 (Bell Laboratories,
Inc., Madison, WI, USA), and all statistical tests were two-sided.
The prevalence of P. aeruginosa and antimicrobial-resistant P.
aeruginosa isolates in a speciﬁc type of pneumonia were
calculated using the following formulae for each study included,
when applicable:
Prevalence of P: aeruginosa
¼ Number of P: aeruginosa isolates
Number of all the detected isolates
100%
Prevalence of antimicrobial  resistant P:aeruginosa
¼ Number of P: aeruginosa isolates resistant to a given agent or MDR=PDR=XDR:P: aeruginosa isolates
Number of all the detected P: aeruginosa isolates
100%
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studies, a random-effects model was applied to carry out all the
meta-analyses using the DerSimonian–Laird method.23 To nor-
malize the distribution of proportions, a logit transformation was
implemented. Increments of 0.5 were added to both the
numerators and denominators in studies with zero events
reported. Differences between the overall prevalence of P.
aeruginosa in different types of pneumonia were examined with
the Q test for heterogeneity,24 and 0.05 was deﬁned as the
threshold of the p-value for statistical signiﬁcance. Egger’s test was
used to evaluate any publication bias,25 and p < 0.1 was regarded
as signiﬁcant. Sensitivity analyses were also conducted to examine
the effect of the methodological quality on the prevalence of P.
aeruginosa by omitting studies with a high risk of bias.
Heterogeneity was assessed by Q test and I2 statistic. A p-value of
<0.05 or an I2 value of >50% indicated substantial heterogeneity.26
For studies on P. aeruginosa prevalence, subgroup analyses were
performed using pre-deﬁned variables, including the level of
hospital, methodological quality, study design, clinical department,
year of study, provincial economic condition, and province. To
graphically demonstrate the geographic distribution of P. aeruginosa
pneumonia, maps were created using MapInfo Professional 11.0
(Pitney Bowes Inc., Stamford, USA) based on the subgroup analyses
by province. The provinces were classiﬁed into higher or lower
economic conditions based on whether the annual gross domestic
product (GDP) per capita of the province in 2013 was higher or lower
than the national average (41 908 RMB) in China.27,28 Statistical
signiﬁcance was deﬁned as non-overlap of the 95% conﬁdence
intervals (CIs) of the prevalence between different subgroups.28
Meta-regressions were used to evaluate the impact of pre-
deﬁned factors on the prevalence of P. aeruginosa and the
corresponding antimicrobial-resistant isolates. The logit-trans-
formed prevalence was deﬁned as the dependent variable, while
the pre-deﬁned factors were the independent variables. The pre-
deﬁned factors were initially selected based on expertise in clinical
microbiology and the possible availability of information in
publications, including clinical department, year of study, and
average age of pneumonia patients. The year of study and the
average age of pneumonia patients were deﬁned as continuous
variables, and the clinical department was set as a dummy
variable. When the prevalence was reported for a multi-year
period, the midpoint of the time interval was considered as the
year of study.29 The deviation from the mean of the average ages of
pneumonia patients reported in the studies included was used as
an independent variable and also deﬁned as continuous. The
number of independent variables ﬁnally entered into the random-
effects meta-regression model using a restricted maximum
likelihood (REML) method was determined by the number of
studies included reporting on the corresponding independent
variables, which should be at least 10 times the number of
independent variables in the model.30 The adjusted R2 was used to
evaluate the meta-regression model. The statistical signiﬁcance of
a single coefﬁcient was tested using a Z-test, and p < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Study inclusion
A total of 12 748 records were identiﬁed and 50 studies were
ﬁnally included; 44 of these reported the prevalence of P.aeruginosa, while 29 contained data on antimicrobial resistance
(Fig. 1). The methodological quality of the studies included is
illustrated in Fig. 2; further details are provided in the Supple-
mentary Material (Figures S1 and S2). Overall, most of the studies
demonstrated a low or moderate risk of bias. A list of the studies
included with a summary of their characteristics is presented in
the Supplementary Material (Tables S2 and S3).
3.2. Prevalence of P. aeruginosa
Table 1 shows the pooled prevalence of P. aeruginosa and the
results of all subgroup analyses. The overall prevalence of P.
aeruginosa in VAP pooled from 28 studies was 19.4% (95% CI 17.6–
21.2%) (Supplementary Material, Figure S3). For HAP, 15 studies
were combined to produce an overall prevalence of 17.8% (95% CI
14.6–21.6%) (Supplementary Material, Figure S4), which was
roughly parallel to that for VAP (p = 0.449). One additional study
reported the P. aeruginosa prevalence in CAP with a point estimate
of 7.7% (15/195), which was signiﬁcantly lower than the
prevalence of VAP (p < 0.001) and HAP (p = 0.001). Furthermore,
a publication bias may exist for the prevalence of both VAP
(p = 0.002) and HAP (p = 0.052). Upon sensitivity analyses, the
pooled prevalence of P. aeruginosa was not materially altered when
studies with a high risk of bias were excluded, with 19.0% (95% CI
17.2–20.9%) for VAP and 17.8% (95% CI 14.4–21.7%) for HAP.
Although differences between subgroups were not statistically
signiﬁcant, the prevalence of P. aeruginosa in patients with VAP or
HAP appeared to be higher in tertiary hospitals or outside intensive
care units (ICUs); the rates also differed across provinces (Fig. 3).
Table 2 presents the results of meta-regression. When a
univariate meta-regression was performed for VAP, the prevalence
of P. aeruginosa did not vary signiﬁcantly relative to the age of the
patients (p = 0.453). The impact of patient age on HAP associated
with P. aeruginosa was not examined since there were only eight
studies with available data. Further multivariate meta-regression
revealed a gradual decline over time during the study period 2007–
2012 in the prevalence of P. aeruginosa in VAP (p < 0.001), whereas
a plateau was observed in HAP during the same period (Fig. 4).
3.3. Prevalence of antimicrobial resistance
The pooled prevalence of P. aeruginosa isolates resistant to the
agents recommended for the initial management of pneumonia is
summarized in Table 3. Among VAP patients, P. aeruginosa
exhibited a varied prevalence of resistance, with a high level of
resistance to gentamicin and a low level of resistance to amikacin.
In addition, the prevalence of isolates resistant to cefepime,
ceftazidime, imipenem, ciproﬂoxacin, amikacin, and gentamicin
remained constant during the study period from 2007 to 2012
(Table 2). With regard to HAP, the point estimates of P. aeruginosa
isolates resistant to the recommended agents ranged from 22.2%
for amikacin to 50.0% for cefoperazone. Moreover, all 15 P.
aeruginosa isolates from CAP patients were sensitive to cefepime,
ceftazidime, cefoperazone-sulbactam, ciproﬂoxacin, and amikacin,
whereas 26.7% (4/15) of the isolates were resistant to levoﬂoxacin
and 20.0% (3/15) to imipenem.
MDR in P. aeruginosa isolates among VAP patients was reported
by two studies in which all the 24 detected isolates showed MDR.
Regarding HAP, 44.4% (4/9) of the P. aeruginosa isolates were found
to be MDR and 18.2% (2/11) to be XDR. MDR isolates accounted for
25% (3/12) of the P. aeruginosa isolates collected from patients with
Fig. 1. Flow diagram of study inclusion.
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available for the prevalence estimate of MDR or XDR in HAP and
for MDR in CAP.
4. Discussion
The prevalence of P. aeruginosa isolates in patients with HAP in
the present systematic review (17.8%) was similar to the rates in
other Asian countries,31 such as Malaysia (18%), Thailand (18%),
and the Philippines (19%), but was remarkably higher when
compared with the results from the NNISS in mainland China
(12.31–13.37%).16 There are several possible reasons for this
difference. First, the results of this review were derived only from
patients who had been diagnosed with HAP, while the Chinese
surveillance system collected samples from the lower respiratory
tract of nosocomially infected patients whose pneumonia status
was unknown. Second, most of the included studies relevant to
HAP (11/15) were conducted after 2007; however, the surveillance
system gathered data from 1999 to 2007. Due to probable
ﬂuctuations in the prevalence of P. aeruginosa in HAP over time,
the variation in study period may also have led to the differencebetween the present review results and those from the surveil-
lance system.
With regard to VAP, a previous systematic review of 119 studies
with earlier publication dates ranging from 2007 to 2012 estimated
that P. aeruginosa accounted for 20.6% of all the isolates from ICU
patients with VAP in mainland China,18 which is roughly identical
to the present ﬁnding (19.9% in ICU cases). Compared with the
previous systematic review, signiﬁcantly fewer studies were
included in the present review due to the exclusion of retrospec-
tive studies. Nevertheless, this review focused on P. aeruginosa
pneumonia of different types without any restrictions on the
clinical department and thus could provide more generalizable
information for both clinicians and policymakers. The temporal
changes in overall P. aeruginosa prevalence were also examined
and the estimates were stratiﬁed by economic condition, hospital
level, province, and clinical department. A gradual declining
change over time in the prevalence of P. aeruginosa isolates
associated with VAP was observed in the meta-regression.
Increasingly frequent reports of infections caused by Acinetobacter
species may have contributed to this change. Acinetobacter species
can utilize multiple mechanisms of resistance and are thus
becoming a more predominant cause of nosocomial infections,
Fig. 2. Summary of risk of bias for all the included studies. (A) Summary of risk of bias for the included studies on P. aeruginosa prevalence. (B) Summary of risk of bias for the
included studies relevant to antimicrobial resistance.
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Acinetobacter species were responsible for 12.63% of nosocomial
infections of the lower respiratory tract from 2005 to 2007; this
rate was only 9.45% from 1999 to 2001.16 In addition, as suggested
in the subgroup analysis, more attention should be paid to P.
aeruginosa infections in tertiary hospitals and clinical departments
outside ICUs for both HAP and VAP.
This review identiﬁed a signiﬁcantly lower P. aeruginosa
prevalence among patients with CAP than seen in those with
VAP and HAP. However, only one study was available for the CAP
prevalence estimate, which underscores the urgent need for future
studies. In addition, the status quo may necessitate further
improvement since the prevalence of P. aeruginosa among patients
with CAP (7.7%) in China seemed notably higher than those in other
countries, such as Germany (0.43%), Australia (1.6%), and Spain
(1.74%).33–35
Another relevant issue in P. aeruginosa pneumonia relates to
polymicrobial infections. In China, the reported rate of poly-
microbial infections linked to P. aeruginosa was 83.7% for HAP and
57.9% for CAP; methicillin-resistant Staphylococcus aureus, Acine-
tobacter baumannii, and Enterobacter cloacae represented the most
frequent co-pathogens, with frequencies of 35.5%, 23.4%, and 9.9%,
respectively.36 The presence of polymicrobial infections appeared
to be associated with the acquisition of MDR among Chinese
patients, which in turn was an independent predictor of poor
outcomes, including higher in-hospital mortality; this observation
was in agreement with the ﬁndings from other populations.37–39
Moreover, patients infected by two or more pathogens had anincreased severity of pneumonia.40 These results suggest the
potential prognostic implications of polymicrobial infections,
particularly in patients with severe pneumonia.
Understanding the risk factors for the occurrence of P.
aeruginosa pneumonia has obvious implications for infection
prevention and management; however, only a few studies on this
issue have been published, and they have yielded inconsistent
results.41 Chronic obstructive pulmonary disease, prolonged
mechanical ventilation (>8 days), and prior use of antimicrobial
agents have been regarded as ‘classical’ predictors of VAP caused
by P. aeruginosa.41,42 Recently, a multinational surveillance study
reassessed the role of these ‘classical’ predictors and found that
none of them was signiﬁcantly associated with P. aeruginosa VAP;
all the other factors assessed (age, immunosuppressive disease or
therapy) were statistically insigniﬁcant as well.43 In accordance
with the previous international study, the present analyses
showed that age had no apparent effect on the occurrence of
VAP due to P. aeruginosa.43 However, it was not possible to assess
other factors for P. aeruginosa pneumonia using meta-regressions
because of the limited data.
Based on the present ﬁndings, the P. aeruginosa isolates
collected from CAP patients appeared to be sensitive to most of
the recommended agents. However, it is necessary to raise
awareness of antimicrobial resistance associated with HAP and
VAP because the prevalence of P. aeruginosa isolates resistant to a
given agent could be much higher than those reported in the USA
and in other Asian countries.7,15 Excessive antimicrobial use is a
major factor that contributes to an increased frequency of
Table 1
Results of subgroup analyses for the prevalence of Pseudomonas aeruginosa
Subgroup Prevalence of P. aeruginosa in VAP Prevalence of P. aeruginosa in HAP
Studies Sample
size
Estimate
(%)a
95% CI (%) I2 (%) Studies Sample
size
Estimate
(%)a
95% CI (%) I2 (%)
Overall 28 10 417 19.4 17.6–21.2 63.5 15 2203 17.8 14.6–21.6 75.4
Hospital level Tertiary 24 3914 19.6 17.8–21.5 44.8 12 1861 19.0 15.3–23.3 76.5
Non-tertiary 1 95 16.8 10.6–25.7 – 2 147 13.0 8.5–19.5 0.0
Unclear 3 6408 17.3 10.5–27.1 86.4 1 195 13.8 9.7–19.4 –
Risk of bias High 2 122 26.3 19.3–34.9 0.0 2 125 18.8 6.8–42.5 81.4
Moderate 16 8286 18.9 16.4–21.8 73.7 12 1883 18.2 14.6–22.4 76.2
Low 10 2009 19.2 17.6–21.0 0.0 1 195 13.8 9.7–19.4 –
Study design Ambispective 1 97 24.7 17.2–34.3 – 3 369 19.3 13.9–26.2 32.8
Prospective 26 10 193 19.3 17.5–21.2 64.9 7 1073 15.9 13.0–19.2 42.1
RCT baseline 1 127 16.5 11.0–24.0 – 5 761 19.9 13.4–28.7 82.4
Clinical department ICU 23 9870 19.9 18.1–21.7 58.6 2 355 9.8 3.6–24.1 80.3
Non-ICU 1 25 32.0 16.9–52.2 – 4 544 19.1 15.3–23.5 33.3
Unclear 4 522 14.9 10.0–21.6 62.2 9 1304 19.1 14.5–24.8 77.7
Province Guangxi 2 132 25.9 19.1–34.0 0.0 2 205 11.1 3.0–33.6 87.0
Jiangsu 1 169 25.4 19.4–32.5 – 1 122 13.9 8.8–21.3 –
Fujian 1 97 24.7 17.2–34.3 – – – – – –
Hebei 1 174 23.6 17.8–30.4 – – – – – –
Shanghai 4 6677 20.9 16.9–25.4 67.8 2 458 14.4 11.5–17.9 0.0
Hubei 1 857 19.7 17.2–22.5 – 1 287 17.8 13.8–22.6 –
Inner Mongolia 1 121 19.0 13.0–27.0 – 1 95 11.6 6.5–19.7 –
Jiangxi 2 172 18.6 13.5–25.1 0.0 – – – – –
Guangdong 6 629 18.1 12.6–25.2 70.4 2 72 16.8 9.8–27.3 0.0
Xinjiang 1 274 17.5 13.5–22.5 – – – – – –
Zhejiang 4 561 17.3 13.5–21.9 39.0 2 157 25.5 19.3–32.9 0.0
Anhui 1 127 16.5 11.0–24.0 – – – – – –
Beijing 1 170 14.7 10.1–20.9 – 1 182 18.1 13.2–24.4 –
Sichuan 2 257 14.0 7.8–23.8 69.9 1 373 30.6 26.1–35.4 –
Henan – – – – – 2 252 18.7 14.3–24.0 0.0
Year
of study
2007 8 7345 22.7 20.7–24.8 27.0 1 287 17.8 13.8–22.6 –
2008 4 1130 22.0 18.7–25.6 22.8 3 423 16.4 13.2–20.3 0.0
2009 4 484 17.3 12.8–23.1 50.0 2 205 11.1 3.0–33.6 87.0
2010 8 847 16.8 14.0–20.1 27.2 3 337 19.6 12.6–29.3 57.1
2011 2 428 14.0 8.3–22.7 74.1 3 547 19.7 10.3–34.4 87.3
2012 2 183 16.4 11.7–22.5 0.0 2 309 21.0 15.5–27.7 44.0
Unclear – – – – – 1 95 11.6 6.5–19.7 –
Economic condition Higher 19 9281 19.5 17.5–21.7 66.0 10 1373 17.1 14.6–19.9 34.8
Lower 9 1136 19.0 15.9–22.5 46.5 5 830 18.4 11.8–27.5 85.6
VAP, ventilator-associated pneumonia; HAP, hospital-acquired pneumonia; CI, conﬁdence interval; RCT, randomized controlled trial; ICU, intensive care unit.
a Random-effects model was used to pool the prevalence of P. aeruginosa.
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sectional studies conducted by the NNISS, the average utilization
rate of antimicrobials among hospitalized patients from 2001 to
2010 was 50.48%, which indicates that antimicrobials were more
frequently prescribed in China than in other countries, such as
Canada (36.3%), Holland (30.9%), and the United Kingdom
(34.7%).44 In addition, when inpatients and outpatients were both
taken into account, only 24.6–39.4% of the antimicrobial prescrip-
tions were considered appropriate (i.e., a standard treatment
regimen and duration were indicated for the patient’s speciﬁc
infection); clinicians tended to prefer broad-spectrum agents,
combination therapy, intravenous administration, and prolonged
treatment durations.45 These prescription patterns were common
across different types of infection. For example, more than 60% of
the antimicrobial prescriptions for CAP had an incorrect dose or
frequency of use, which might be further combined with errors in
the duration or choice of agents as well as individual patient
deviations from the prescribed therapy.46–48 Key factors underly-
ing the frequent and improper use of antimicrobials in China may
include a lack of professional training and public education, lax
regulations and supervision, and payment policies that encourage
clinicians to prescribe antimicrobials.45,48
P. aeruginosa is intrinsically susceptible to all of the agents
recommended in clinical practice guidelines; however, it can
acquire further resistance to these agents through almost all theknown mechanisms of antimicrobial resistance.49 In particular, the
accumulation of unrelated resistance mechanisms in P. aeruginosa
may lead to severe infections caused by MDR or even PDR isolates,
compromising advanced treatment protocols that are inherently
reliant on effective infection control to deliver their life-saving
potential, including trauma surgery, cancer chemotherapy, and
stem cell or organ transplantation.45,50 b-Lactamase production,
especially extended-spectrum b-lactamases (ESBLs), remains the
dominant contributing factor to acquired b-lactam resistance in P.
aeruginosa.51 The frequency of ESBL-producers among P. aerugi-
nosa isolates in China (35.3–64.7% depending on the ward) has
tended to be higher than in other countries, such as India (22.2%)
and Belgium (2.2%); in addition, the ESBLs identiﬁed in Chinese
isolates were very diverse, including the worldwide-spread PER
and VEB types, as well as the rarely reported ESBLs of the CTM-X,
SHV, and TEM types.50,52–54 ESBLs confer resistance to expanded-
spectrum cephalosporins (cefoperazone, cefepime, and ceftazi-
dime), while their activity can be suppressed by b-lactamase
inhibitors.50 Accordingly, P. aeruginosa exhibited low resistance to
cefoperazone combined with sulbactam in the present review.
Among b-lactams, carbapenems (imipenem and meropenem)
are the most potent agents for MDR P. aeruginosa due to their
stability against ESBLs.55 However, the results of this review
revealed a heavy burden of carbapenem-resistant P. aeruginosa
(CRPA) in Chinese hospitals, which leaves even fewer therapeutic
Fig. 3. Province distribution of P. aeruginosa pneumonia in mainland China. (A) Province distribution of P. aeruginosa in ventilator-associated pneumonia (VAP) in mainland
China. (B) Province distribution of P. aeruginosa in hospital-acquired pneumonia (HAP) in mainland China. The maps were generated using Mapinfo Professional 11.0 software
based on the subgroup analyses by province. Random-effects model was used to pool the provincial prevalence of P. aeruginosa.
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Chinese P. aeruginosa isolates was driven mainly by a deﬁciency of
OprD and may or may not be accompanied by the overexpression
of MexAB-OprM or metallo-lactamase (MBL) production.56,57
Although relatively uncommon among CRPA in China, with a
proportion of 8.5% compared to 35.9% in Brazil and 38% in Russia,
MBL-producing P. aeruginosa isolates have caused great concern
since they hydrolyze all b-lactams (except monobactams) and
cannot be inhibited by clinically available b-lactamase inhibi-
tors.56,58,59 It is also noteworthy that P. aeruginosa might produce
MBLs through speciﬁc genetic elements that are transferable toother Gram-negative species, which could therefore increase the
overall resistance rates.60
Most frequently, P. aeruginosa expresses ﬁve kinds of amino-
glycoside-modifying enzymes, but only one confers resistance to
amikacin. In contrast, the remaining four afford resistance to
gentamicin.49 Similarly, the pooled prevalence of P. aeruginosa
isolates resistant to amikacin in this review was much lower than
gentamicin. Furthermore, methylation of 16S rRNA has recently
emerged as an unusual (but clinically signiﬁcant) mechanism of
conferring resistance to all useful aminoglycosides in a few
countries, including China.61 Like MBLs, the genes responsible
Table 2
Results of meta-regression for Pseudomonas aeruginosa prevalence and antimicrobial resistance
Pneumonia Dependent variablea Independent
variableb
Studies Coefﬁcient SE OR 95% CI (OR) p-Value Adjusted R2
Univariate meta-regressionc
HAP P. aeruginosa prevalence Year of study 14 0.078 0.074 1.081 0.936–1.248 0.292 10.44
VAP P. aeruginosa prevalence Year of study 28 0.116 0.028 0.891 0.843–0.941 <0.001 74.82
P. aeruginosa prevalence Average age of
pneumonia patients
13 0.004 0.006 1.004 0.993–1.016 0.453 0.00
Prevalence of ceftazidime-resistant P. aeruginosa Year of study 15 0.052 0.140 0.949 0.722–1.247 0.707 0.00
Prevalence of amikacin-resistant P. aeruginosa Year of study 13 0.016 0.182 0.984 0.689–1.405 0.930 0.00
Prevalence of cefepime-resistant P. aeruginosa Year of study 13 0.142 0.138 0.868 0.663–1.136 0.302 0.00
Prevalence of imipenem-resistant P. aeruginosa Year of study 11 0.161 0.119 0.852 0.674–1.075 0.177 0.00
Prevalence of ciproﬂoxacin-resistant P. aeruginosa Year of study 12 0.084 0.183 0.920 0.642–1.317 0.648 0.00
Prevalence of gentamicin-resistant P. aeruginosa Year of study 11 0.215 0.189 1.240 0.857–1.795 0.255 0.00
Multivariate meta-regressionc
VAP P. aeruginosa prevalence Year of study 24 0.114 0.023 0.892 0.853–0.933 <0.001 95.95
Clinical department
ICU - - 1.000 - -
Non-ICU 0.674 0.432 1.962 0.841–4.576 0.119
SE, standard error; OR, odds ratio; CI, conﬁdence interval; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; ICU, intensive care unit.
a The logit-transformed prevalence was deﬁned as the dependent variable.
b The year of the study was deﬁned as a continuous variable and the clinical department was set as a dummy variable; the deviation from the mean of the average ages of
pneumonia patients reported in the studies included was used as the independent variable and also deﬁned as continuous.
c Random-effects meta-regression model with restricted maximum likelihood (REML) method was used to conduct meta-regression.
Fig. 4. Pooled prevalence of P. aeruginosa pneumonia in mainland China at different
study periods, with corresponding 95% conﬁdence intervals (CIs).
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them with the potential to spread horizontally.50 In addition, the
high-level ﬂuoroquinolone resistance in P. aeruginosa might be
attributable to the interaction of efﬂux pumps and mutations of the
genes that encode DNA gyrase and topoisomerase IV.49
Clinicians in China are gradually recognizing the growing
threat of antimicrobial resistance in P. aeruginosa largely due to
the emergence and dissemination of transferrable resistance
determinants, notably those encoding ESBLs or MBLs; however,
relevant molecular studies and epidemiological data remain
scarce.62 In the absence of the further development of novel
antimicrobial agents in the near future, surveillance of the
phenotypic and molecular characteristics of resistant P.
aeruginosa should be enhanced to help preserve the effective-
ness of agents used as last-resort therapies in Chinese clinical
settings.Delays in the administration of treatment have contributed to
excess mortality; therefore, empirical therapy is still essential
before microbiology results are available and is recommended in
the guidelines for the management of pneumonia.1 However, a
high prevalence of resistance may lead to an increased probability
of inappropriate initial empirical antimicrobial therapy, which is
associated with poor clinical and economic outcomes.13 To
increase the likelihood that adequate antimicrobial treatment
will be prescribed, drug susceptibility patterns of the suspected
pathogen should also be considered when designing an empirical
therapy regimen. In this review, the relatively low rate of P.
aeruginosa isolates resistant to amikacin and imipenem suggests
the potential use of amikacin plus imipenem as the therapy
regimen of choice for the initial management of suspected HAP
caused by P. aeruginosa in mainland China. With respect to VAP,
however, the combination of amikacin with cefoperazone-
sulbactam may provide a broader spectrum of coverage than
other agents. Apart from the population-level data on resistance,
consideration of patient characteristics, such as prior antimicrobial
use, is also helpful in guiding the choice of empirical therapy.51 For
example, in vitro and in vivo studies have already demonstrated
that carbapenem exposure facilitates CRPA infections and may also
increase the risk of acquiring resistance to cephalosporins by
inducing AmpC.62 Likewise, previous use of a ﬂuoroquinolone has
been associated with the development of VAP due to piperacillin-
resistant P. aeruginosa.41
There are several potential limitations of the present
systematic review. First, the methodological quality of the studies
included was the main concern for the pooled prevalence,
because less than half of the studies demonstrated a low risk of
bias. However, the study quality did not appear to be the main
source of heterogeneity according to the subgroup analyses.
Sensitivity analyses that were carried out by omitting studies
with a high risk of bias produced robust results as well. Second,
possible publication bias should be considered when evaluating
the results. Additional studies may also be needed to conﬁrm
some of the pooled prevalences derived from the limited number
of included studies.
Table 3
Results of pooled prevalence of antimicrobial-resistant Pseudomonas aeruginosa isolates
Antimicrobial agent Prevalence of resistant P. aeruginosa in HAP Prevalence of resistant P. aeruginosa in VAP
Studies Sample size Estimate (%)a 95% CI (%) I2 (%) Studies Sample size Estimate (%)a 95% CI (%) I2 (%)
b-lactam
Cefoperazone 1 22 50.0 30.2–69.8 - 5 143 43.0 19.6–70.0 82.3
Cefepime 6 261 35.3 29.3–41.9 9.9 13 274 38.5 28.3–49.9 63.7
Ceftazidime 7 276 34.3 25.3–44.5 59.2 15 477 40.3 30.4–51.0 71.9
Piperacillin 5 246 47.9 30.7–65.6 84.8 7 157 47.3 30.8–64.4 74.5
Imipenem 8 309 22.9 10.3–43.6 87.9 11 418 41.1 32.3–50.5 60.1
Meropenem 4 201 35.7 22.6–51.3 75.1 6 137 38.9 27.6–51.5 46.9
Cefoperazone–sulbactam 5 210 33.9 24.5–44.7 52.6 7 216 35.2 24.6–47.4 61.5
Piperacillin–tazobactam 6 225 30.2 17.5–46.8 77.6 9 226 38.9 29.3–49.5 52.9
Antipseudomonal quinolone
Levoﬂoxacin 6 241 36.8 24.3–51.4 75.5 9 241 38.3 26.2–52.0 68.4
Ciproﬂoxacin 5 185 35.0 20.9–52.3 75.4 12 427 46.8 33.4–60.6 79.1
Aminoglycoside
Amikacin 7 294 22.2 13.8–33.6 71.7 13 475 22.5 14.3–33.6 76.6
Gentamicin 5 203 42.4 30.4–55.3 62.9 11 418 51.1 37.7–64.4 81.7
HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; CI, conﬁdence interval.
a Random-effects model was used to pool the prevalence of antimicrobial-resistant P. aeruginosa isolates.
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